miRNA biomarker | GenomeWeb

miRNA biomarker

Researchers in the US and Ukraine built a microRNA-based classifier to categorize infants as affected or unaffected.

Researchers from Northwestern University uncovered five circulating microRNAs that differentiate patients with very high- and low-risk prostate cancer.

A team of German researchers identified the four-microRNA signature and said it might inform treatment decisions.

The company sees microRNAs as the ideal blood-based biomarker for diagnosing and monitoring a number of diseases at the point of care and in the developing world.

The test could provide an early diagnosis of breast cancer by examining a handful of miRNA, microRNA, and proteomic biomarkers from urine samples. 

The International Thyroid Congress and Annual Meeting of the American Thyroid Association announced studies validating diagnostics tests for several companies.

NIH researchers have uncovered a blood-based microRNA signature that may be able to tell which patients with precursor disease may progress to myeloma.

The grant is being provided under the NIH's Extracellular RNA Communication program, which was set up to study the role of molecules such as microRNAs.

The company has begun establishing partnerships with medical centers for a large prospective study of its test for identifying aggressive tumors.

The partners will try to validate the ability of has-miR-31-3p to predict which patients may benefit from anti-EGFR therapy.

Pages

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.